ALK variants Differentially Modulate Neuroblastoma Tumor Behavior and Transcriptome in a Cellular Context-Dependent Manner
El Natour MayaiD, Lucie Vivancos StaliniD, Nastassia GobetiD, Viviane PraziD, Katia Balmas BourloudiD, Nicolas JauquieriD, Isabelle Janoueix‐LeroseyiD, Nicolò RiggiiD, Raffaele RenellaiD, Annick Mühlethaler‐MottetiD
Abstract
High-risk neuroblastoma remains a major clinical challenge despite intensive multimodal treatment. Alterations in the anaplastic lymphoma kinase (ALK) gene are frequent in NB and correlate with poor outcome. ALK-F1174L and ALK-R1275Q are the most prevalent activating mutations, but their specific effects on tumor behavior remain unclear. Here, we compared the impacts of ALK-wild-type (wt), ALK-F1174L and ALK-R1275Q in several NB xenograft models. In the SK-N-Be2c model, ALK-F1174L mediated numerous transcriptomic alterations without affecting tumor behavior. In GIMEN cells, only ALK-F1174L and ALK-R1275Q conferred tumorigenicity with distinct growth kinetics and transcriptional programs. In the mesenchymal SH-EP model, ALK variants induced distinct phenotypes, with ALK-wt and ALK-F1174L promoting partial transition toward neuroblastic identity. All ALK variants induced lung metastases, but with allele-specific dissemination patterns. Transcriptomic profiling of SH-EP tumors and corresponding metastases revealed partly opposing pathway regulation between ALK-F1174L and ALK-R1275Q. Overall, ALK variants differentially modulate NB behavior in a context-dependent manner.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neuroblastoma-associated ALK variants have distinct cellular and biochemical activities
Anna Magdalena Wulf, Stuart Lutimba, … Karen J. Liu·bioRxiv·Sep 25, 2025
- ALK R1275Q mutation drives expansion of SCP-like cells during sympathoadrenal commitment and primes neuroblastoma initiation.
Mingzhi Liu, Panagiotis Alkinoos Polychronopoulos, … Margareta Wilhelm·bioRxiv·Jan 27, 2026
- ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN
Marcus Borenäs, Dan Emil Lind, … Ruth Helen Palmer·bioRxiv·Jul 17, 2025
- ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to ATR inhibition
M. Borenäs, G. Umapathy, … R. H. Palmer·bioRxiv·Aug 30, 2023
- COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.
E. Tucker, I. Jimenez, … G. Schleiermacher·Clinical Cancer ResearchPeer-reviewed·Apr 3, 2023
- DUSP6 is transcriptionally upregulated by activated ALK and cooperates with ALK signaling to reduce lorlatinib sensitivity in neuroblastoma cells
Elliott M. Thompson, Vruti Patel, … Andrew W. Stoker·bioRxiv·Jun 11, 2026